A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce federal regulations on compounded we ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

Fact checked by Nick Blackmer “Microdosing” GLP-1 drugs like Ozempic is gaining attention on social media, but doctors say it ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Mara Nissley has a rare disorder that causes her brain to swell as if she has a tumor. Losing weight can help treat the condition, called pseudotumor cerebri. Last year, her doctor recommended she ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...

Forbes contributors publish independent expert analyses and insights. Dr Margie Warrell emboldens people to live and lead more bravely.

(The Hill) – A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro.

Out of reach Many health insurance policies do not cover GLP-1 medications prescribed ... said he’s lost 18 pounds since starting to take Zepbound about a month ago, with no noticeable side ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound ... it would not take any enforcement ...